Mobile Site ›

The Use of Genetics in Guiding Therapy

Clopidogrel (Plavix)

Slide 7

June 2012

Clopidogrel, or Plavix, is a commonly used anti-platelet drug which is administered as an inactive prodrug and metabolized to its active form by CYP or cytochrome P450 enzymes. It is used to reduce atherosclerotic events in patients with acute coronary syndrome and/or following Percutaneous Coronary Intervention or PCI. It is often given as alternative to aspirin or in combination with aspirin which is known as dual antiplatelet therapy. There is a highly variable response to clopidogrel where it is efficacious in some, and not efficacious in others. This can be due to many variables including underdosing and interactions with CYP inhibitors and substrates, as well as genetics.

Clopidogrel (Plavix)


Jump to section: